Best response to lenalidomide, adriamycin, and dexamethasone (RAD) in relation to dose levels: intention-to-treat analysis
| Best response (according to EBMT criteria, Bladé et al14 ) . | Patients, n (%) per study dose level . | ||
|---|---|---|---|
| 1 to 4+ G: 22 (32) . | 5+ G: 47 (68) . | Total 69 (100) . | |
| Complete response | 0 (0) | 10 (21) | 10 (14.5) |
| Very good partial response | 5 (23) | 25 (53) | 30 (43) |
| Partial response | 7 (32) | 1 (2) | 8 (11.5) |
| Stable disease | 6 (27) | 7 (15) | 13 (19) |
| Progression | 2 (9) | 3 (6) | 5 (7) |
| Not evaluable | 2 (9) | 1 (2) | 3 (4) |
| Best response (according to EBMT criteria, Bladé et al14 ) . | Patients, n (%) per study dose level . | ||
|---|---|---|---|
| 1 to 4+ G: 22 (32) . | 5+ G: 47 (68) . | Total 69 (100) . | |
| Complete response | 0 (0) | 10 (21) | 10 (14.5) |
| Very good partial response | 5 (23) | 25 (53) | 30 (43) |
| Partial response | 7 (32) | 1 (2) | 8 (11.5) |
| Stable disease | 6 (27) | 7 (15) | 13 (19) |
| Progression | 2 (9) | 3 (6) | 5 (7) |
| Not evaluable | 2 (9) | 1 (2) | 3 (4) |